IPV
| Question | Evidence-Based, Logic-Driven Response (IPV) |
|---|---|
| What is my child’s actual risk of dying from this disease, statistically? | In the modern U.S., the risk of polio infection, paralysis, or death is essentially zero. The last natural U.S. polio case was in 1979. Sanitation improvements—not the vaccine alone—eliminated wild polio in most developed nations. Risk to a breastfed, healthy child in the U.S. is virtually non-existent. |
| Have you ever lost an unvaccinated patient to polio? Any patient lost due to the IPV vaccine? | No practicing pediatrician today has lost a U.S. patient to polio. On the other hand, IPV-related injuries (including death, paralysis, seizures) are documented in VAERS and VICP. In the past, oral polio vaccine (OPV) caused thousands of paralysis cases, which is why it was pulled from the U.S. schedule in 2000. |
| Odds of any side effect? Severe side effect? Compared to natural disease? | - Mild: redness, swelling, irritability (~10%). - Severe: anaphylaxis, seizures, high fever, SIDS, encephalopathy. - Death from natural polio in the U.S. today: essentially 0. Death from vaccine: nonzero, though rare. |
| Most severe adverse event you’ve seen? Most common? | Common: soreness, fever. Severe: seizures, infant apnea, hypotonia, death. Cases of paralysis post-IPV are extremely rare but exist in data. Most severe events occur in combination with other vaccines. |
| Worst-case outcome from insert or VAERS? How many deaths? | Package inserts list: anaphylaxis, seizures, Guillain-Barré syndrome (GBS), SIDS, and death. VAERS includes over 100 deaths linked temporally to IPV, especially when given alongside other vaccines. |
| Recent VAERS reports? Severity? | Ongoing reports include seizures, high fevers, sudden death, and apnea. Most IPV doses are administered with DTaP and Hep B, complicating attribution. Still, temporal proximity is consistent in some death cases. |
| How many VAERS reports have you filed? Do you follow up? | Pediatricians typically do not file VAERS reports. Most do not follow up unless symptoms are severe and persistent. Parents rarely receive post-vaccination check-ins. |
| Will you test antibody titers before boosters? Why a uniform schedule? | No titers are checked. The CDC recommends 4 IPV doses regardless of exposure risk, immunity status, or individual health history. No allowance is made for personal immunity levels. |
| Can you guarantee IPV won’t cause autoimmune, neurological, or developmental harm? | No. While IPV lacks a live virus, it includes formaldehyde, aluminum-based adjuvants, 2-phenoxyethanol, and other neurotoxic ingredients. Long-term safety in developing infants has not been adequately studied. |
| Was this tested against a true saline placebo? | No. IPV was tested against other vaccines or non-saline substances, invalidating true safety comparison. |
| Do you treat unvaccinated patients? Ever advised skipping IPV for a low-risk child? | Almost no doctors recommend skipping IPV—even for children in completely polio-free regions. Policy adherence outweighs individual risk assessment. |
| If a child reacts severely, will you alter the schedule? | Reactions (unless anaphylactic) are almost always treated as coincidental. Most providers will continue the schedule, even after seizures or lethargy. |
| Can we review the insert and ingredients together? | IPV contains: formaldehyde, 2-phenoxyethanol, aluminum, residual calf serum proteins. Insert lists death, encephalopathy, GBS, and seizures. Most pediatricians never present or review the insert unless asked explicitly. |
| How do you assess causation vs. coincidence in adverse events? | Most providers default to “coincidence,” especially with IPV, assuming it's “safer.” However, serious events post-IPV do occur, particularly when given in combination with other shots, and are not investigated thoroughly. |
| Are there long-term outcome studies comparing vaccinated vs. unvaccinated children? | No. No studies comparing polio-vaccinated vs. unvaccinated children for neurological or autoimmune disease incidence. NIH and CDC have refused to fund such studies. |
| Are you concerned about how the vaccine schedule has grown? | IPV replaced OPV in 2000. Today, IPV is just one of many shots given at 2, 4, 6, and 18 months. When given with DTaP, Hep B, PCV, and rotavirus, toxic load exceeds tested levels. Pediatricians rarely question cumulative burden. |
| Have you noticed an increase in chronic conditions over the past 20 years? | The rise in autism, seizures, asthma, and autoimmune disease parallels the expansion of the vaccine schedule. IPV may be a small part, but contributes to the overall immune stimulation and toxicant load. |
| If a serious adverse event occurred post-IPV, would you report it and acknowledge it? | Most providers would not. Even if the timing is immediate, the assumption is “correlation ≠ causation.” Parents are often blamed or told it was “just one of those things.” |
| Are you under institutional or insurance pressure to vaccinate on schedule? | Yes. Vaccine compliance affects reimbursements, public health reporting, and professional standing. Deviation from the schedule is discouraged or penalized. |
| Do you understand the Vaccine Injury Compensation Program? Ever had a patient file? | IPV injuries (GBS, death, anaphylaxis) have been compensated under VICP. However, most pediatricians do not inform patients of this right, and few know how to assist in the filing process. |